Die Allergen-Immuntherapie – State of the Art 2020

Die Allergen-Immuntherapie (AIT) ist die einzige Therapieoption für Patienten mit IgE-vermittelten inhalativen Allergien, welche nachweislich einen Krankheits-modifizierenden und (sekundär-)präventiven Effekt hat [1], [2], [3], [4], da sie die zugrunde liegenden immunologischen Pathomechanismen dieser Erkrankungen beeinflusst [5], [6]. Nach der Erstbeschreibung der AIT durch Noon im Jahre 1911 sind viele innovative Wege beschritten worden, um die Wirksamkeit und Sicherheit der AIT weiter zu optimieren [7] ([Abb. 1]).

Publication History

Article published online:
17 November 2020

• Literatur

• 1 Jutel M, Agache I, Bonini S. et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol 2015; 136: 556-568
• 2 Kristiansen M, Dhami S, Netuveli G. et al. Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis. Pediatr Allergy Immunol 2017; 28: 18-29
• 3 Muraro A, Roberts G, Halken S. et al. EAACI guidelines on allergen immunotherapy: Executive statement. Allergy 2018; 73: 739-743
• 4 Pfaar O, Bachert C, Bufe A. et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int 2014; 23: 282-319
• 5 Jutel M, Agache I, Bonini S. et al. International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol 2016; 137: 358-368
• 6 Pfaar O, Agache I, de Blay F. et al. Perspectives in allergen immunotherapy: 2019 and beyond. Allergy 2019; 74 (Suppl. 108) 3-25
• 7 Durham SR, Leung DY. One hundred years of allergen immunotherapy: time to ring the changes. J Allergy Clin Immunol 2011; 127: 3-7
• 8 European Medicines Agency. Commitee for medicinal products for human use (CHMP): Guideline on the Clinical Development of Products for Specific Immunotherapy for The Treatment of Allergic Diseases (CHMP/EWP/18504/2006). 2008 Online (last access: 04.10.2020): https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-products-specific-immunotherapy-treatment-allergic-diseases_en.pdf
• 9 Verordnung über die Ausdehnung der Vorschriften über die Zulassung der Arzneimittel auf Therapieallergene, die für einzelne Personen auf Grund einer Rezeptur hergestellt werden, sowie über Verfahrensregelungen der staatlichen Chargenprüfung (Therapieallergene-Verordnung). Bundesgesetzbl 2008; 51: 2177-2178
• 10 Dhami S, Nurmatov U, Arasi S. et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy 2017; 72: 1597-1631
• 11 Dhami S, Kakourou A, Asamoah F. et al. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy 2017; 72: 1825-1848
• 12 Roberts G, Pfaar O, Akdis CA. et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy 2018; 73: 765-798
• 13 Canonica GW, Cox L, Pawankar R. et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. The World Allergy Organization journal 2014; 7: 6
• 14 Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI). Tabellen zur „S2k-Leitlinie zur (allergen-)spezifischen Immuntherapie (SIT)“. Online (last access: 04.10.2020): https://dgaki.de/leitlinien/s2k-leitlinie-sit/
• 15 Breiteneder H, Peng YQ, Agache I. et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy 2020;
• 16 Pfaar O, Demoly P, Gerth van Wijk R. et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 2014; 69: 854-867
• 17 Pfaar O, Agache I, Bergmann KC. et al. Placebo effects in allergen immunotherapy – an EAACI Task Force Position Paper. Allergy 2020;
• 18 Pfaar O, Bastl K, Berger U. et al. Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis – an EAACI position paper. Allergy 2017; 72: 713-722
• 19 Pfaar O, Calderon MA, Andrews CP. et al. Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an EAACI Position Paper. Allergy 2017; 72: 1035-1042
• 20 Shamji MH, Kappen JH, Akdis M. et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy 2017; 72: 1156-1173
• 21 Casale TB, Stokes JR. Future forms of immunotherapy. J Allergy Clin Immunol 2011; 127: 8-15 quiz 16–17
• 22 Pfaar O, Lou H, Zhang Y. et al. Recent developments and highlights in allergen immunotherapy. Allergy 2018; 73: 2274-2289
• 23 Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI). AIT und COVID-19. Online (last access: 04.10.2020): https://dgaki.de
• 24 Klimek L, Pfaar O, Worm M. et al. Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA: Position paper of the German ARIA Group(A) in cooperation with the Austrian ARIA Group(B), the Swiss ARIA Group(C), German Society for Applied Allergology (AEDA)(D), German Society for Allergology and Clinical Immunology (DGAKI)(E), Society for Pediatric Allergology (GPA)(F) in cooperation with AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO-KHC(G) and the European Academy of Allergy and Clinical Immunology (EAACI). Allergol Select 2020; 4: 44-52
• 25 Pfaar O, Klimek L, Worm M. et al. [Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide)]. Laryngorhinootologie 2020; 99: 676-679
• 26 Pfaar O, Torres MJ, Akdis CA. COVID-19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS-CoV-2 infection and care of allergy patients. Allergy 2020;
• 27 Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI). Umfrage zu COVID-19 und AIT. Online (last access: 04.10.2020): https://www.survio.com/survey/d/Z9C2A1E7K8Z5A0A3R
• 28 Pfaar O, Gerstlauer M, Saloga J, Vogelberg C, Kleine-Tebbe J. Allergen-Immuntherapie (Hyposensibilisierung). In: Klimek L, Vogelberg C, Werfel T, Hrsg. Weißbuch Allergie in Deutschland 4. überarbeitete und erweiterte Auflage. Springer Medizin Verlag; 2018: 284-295